This company has been acquired
Applied Genetic Technologies Balance Sheet Health
Financial Health criteria checks 3/6
Key information
92.62%
Debt to equity ratio
US$16.34m
Debt
| Interest coverage ratio | n/a |
| Cash | US$34.24m |
| Equity | US$17.65m |
| Total liabilities | US$39.69m |
| Total assets | US$57.33m |
Recent financial health updates
Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Financial Position Analysis
Short Term Liabilities: AGTC's short term assets ($37.2M) exceed its short term liabilities ($26.6M).
Long Term Liabilities: AGTC's short term assets ($37.2M) exceed its long term liabilities ($13.1M).
Debt to Equity History and Analysis
Debt Level: AGTC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGTC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGTC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/01 02:50 |
| End of Day Share Price | 2022/11/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Genetic Technologies Corporation is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Yun Zhong | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |